Background: The role of salivary-specific IgG4 and IgA in subcutaneous immunotherapy (SCIT) is not well defined. We aimed to investigate the change of IgG4 and IgA in both serum and saliva and their correlations with IgE-blocking-factor (IgE-BF) during SCIT. Method: 307 Dermatophagoides pteronyssinus (DP) allergic rhinitis and/or asthma patients were recruited for this study. 286 patients received DP-SCIT for 1 year. Twenty-one patients received only symptomatic treatment. DP-, Der p 1-, and Der p 2-specific IgE in serum, specific-IgG4 and Der p 2-specific IgA1 and IgA2 in both serum and saliva were measured at timepoints 0, 4, and 12 months during DP-SCIT. Correlation between salivary and serological IgG4, IgA, and their correlation with DP-specific IgE-BF measured in serum was evaluated. Results: During DP-SCIT, the allergen-specific IgG4 in both saliva and serum increased and correlated significantly, the correlation becomes stronger over the treatment time. DP-specific IgE-BF significantly correlated with DP-specific IgG4 in serum (p #x3c; 0.0001) at different timepoints and in saliva at 12 months of SCIT (p #x3c; 0.01). No change in Der p 2-specific IgA during DP-SCIT was observed, and the IgA in serum did not correlate with IgA in saliva. There was no correlation between DP IgE-BF and Der p 2-specific IgA in serum or saliva. The control group did not exhibit significant changes in any antibody level measured. Conclusion: The IgE blocking activity induced by DP-SCIT treatment correlated with specific IgG4 and not IgA. The IgG4 in saliva correlates with serum IgG4 and can be an alternative immunological marker beyond 1 year of SCIT treatment.
Int Arch Allergy Immunol

中文翻译：

---

由屋尘螨皮下免疫疗法诱导的 IgE 阻断活性与特定 IgA 无关，但与血清和唾液中的 IgG4 相关

背景：唾液特异性 IgG4 和 IgA 在皮下免疫治疗 (SCIT) 中的作用尚未明确。我们旨在研究 SCIT 期间血清和唾液中 IgG4 和 IgA 的变化及其与 IgE 阻断因子 (IgE-BF) 的相关性。方法： 307尘螨(DP) 过敏性鼻炎和/或哮喘患者被招募用于本研究。286 名患者接受了为期 1 年的 DP-SCIT。21 名患者仅接受对症治疗。在 DP-SCIT 期间的 0、4 和 12 个月的时间点测量血清中的 DP-、Der p 1- 和 Der p 2 特异性 IgE，血清和唾液中的特异性 IgG4 和 Der p 2 特异性 IgA1 和 IgA2 . 评估了唾液和血清学 IgG4、IgA 之间的相关性，以及它们与血清中测量的 DP 特异性 IgE-BF 的相关性。结果：在 DP-SCIT 期间，唾液和血清中的过敏原特异性 IgG4 增加并显着相关，相关性随着治疗时间的推移而变得更强。DP 特异性 IgE-BF 与血清中 DP 特异性 IgG4 显着相关（p#x3c; 0.0001) 在不同时间点和 SCIT 12 个月的唾液中 ( p #x3c; 0.01)。在 DP-SCIT 期间没有观察到 Der p 2 特异性 IgA 的变化，并且血清中的 IgA 与唾液中的 IgA 没有相关性。DP IgE-BF 与血清或唾液中的 Der p 2 特异性 IgA 之间没有相关性。对照组在测量的任何抗体水平上没有表现出显着变化。结论： DP-SCIT 治疗诱导的 IgE 阻断活性与特异性 IgG4 相关，而不是与 IgA 相关。唾液中的 IgG4 与血清 IgG4 相关，可以作为 SCIT 治疗 1 年后的替代免疫标志物。
Int Arch 过敏免疫